After progression-free survival data for satraplatin failed to wow an FDA advisory committee in July, GPC Biotech AG, along with partners Pharmion Corp. and Spectrum Pharmaceuticals Inc., hoped the drug's overall survival data would be impressive enough to clear the way for approval in second-line hormone-refractory prostate cancer. (BioWorld Today) Read More
